Michael Liebrenz

Summary

Affiliation: Psychiatric University Hospital
Country: Switzerland

Publications

  1. pmc High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001, Zurich, Switzerland
    J Med Case Rep 6:125. 2012
  2. ncbi Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    Swiss Med Wkly 137:234-6. 2007
  3. ncbi Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    World J Biol Psychiatry 10:640-3. 2009
  4. doi Agonist substitution--a treatment alternative for high-dose benzodiazepine-dependent patients?
    Michael Liebrenz
    Research Group on Substance Use Disorders, Psychiatric University Hospital Zurich, Selnaustrasse 9, Zurich, Switzerland
    Addiction 105:1870-4. 2010
  5. pmc Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia
    Anna Buadze
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001 Zurich, Switzerland
    Harm Reduct J 7:22. 2010
  6. ncbi Patient's perceptions of the cannabis-psychosis link--a systematic review
    Anna Buadze
    University of Zurich, Clinic of Affective Disorders and General Psychiatry, Lenggstrasse 31, 8032 Zurich, Switzerland
    Curr Pharm Des 18:5105-12. 2012

Collaborators

Detail Information

Publications6

  1. pmc High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001, Zurich, Switzerland
    J Med Case Rep 6:125. 2012
    ..abstract:..
  2. ncbi Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    Swiss Med Wkly 137:234-6. 2007
    ..Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms...
  3. ncbi Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
    Michael Liebrenz
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland
    World J Biol Psychiatry 10:640-3. 2009
    ..This single-case trial was conducted to explore the duration of improvement and the effects of a second administration on the clinical outcome...
  4. doi Agonist substitution--a treatment alternative for high-dose benzodiazepine-dependent patients?
    Michael Liebrenz
    Research Group on Substance Use Disorders, Psychiatric University Hospital Zurich, Selnaustrasse 9, Zurich, Switzerland
    Addiction 105:1870-4. 2010
    ..Cognitive impairments, the most problematic side effects of substitution treatment with benzodiazepines, could possibly be minimized by using an optimal agonist...
  5. pmc Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia
    Anna Buadze
    Psychiatric University Hospital, Research Group on Substance Use Disorders, Selnaustrasse 9, 8001 Zurich, Switzerland
    Harm Reduct J 7:22. 2010
    ....
  6. ncbi Patient's perceptions of the cannabis-psychosis link--a systematic review
    Anna Buadze
    University of Zurich, Clinic of Affective Disorders and General Psychiatry, Lenggstrasse 31, 8032 Zurich, Switzerland
    Curr Pharm Des 18:5105-12. 2012
    ..Despite the heterogeneity of the included studies, findings are comparable and support the robustness of this review. Limitations and implications for clinicians and psychosis research are discussed...